DK2178900T3 - Oprensning af pegylerede polypeptider - Google Patents

Oprensning af pegylerede polypeptider

Info

Publication number
DK2178900T3
DK2178900T3 DK08784775.2T DK08784775T DK2178900T3 DK 2178900 T3 DK2178900 T3 DK 2178900T3 DK 08784775 T DK08784775 T DK 08784775T DK 2178900 T3 DK2178900 T3 DK 2178900T3
Authority
DK
Denmark
Prior art keywords
pegyled
polypeptides
purification
pegyled polypeptides
Prior art date
Application number
DK08784775.2T
Other languages
English (en)
Inventor
Josef Burg
Klaus Reichert
Axel Schroth
Hartmut Schurig
Axel Wessner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40120288&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2178900(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK2178900T3 publication Critical patent/DK2178900T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK08784775.2T 2007-07-17 2008-07-15 Oprensning af pegylerede polypeptider DK2178900T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07013959 2007-07-17
PCT/EP2008/005767 WO2009010270A2 (en) 2007-07-17 2008-07-15 Reinigung pegylierter polypeptide

Publications (1)

Publication Number Publication Date
DK2178900T3 true DK2178900T3 (da) 2012-06-25

Family

ID=40120288

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08784775.2T DK2178900T3 (da) 2007-07-17 2008-07-15 Oprensning af pegylerede polypeptider

Country Status (21)

Country Link
US (2) US8138317B2 (da)
EP (1) EP2178900B1 (da)
JP (2) JP5307808B2 (da)
KR (1) KR101163297B1 (da)
CN (1) CN101889023B (da)
AR (2) AR067537A1 (da)
AT (1) ATE556086T1 (da)
AU (1) AU2008277887B2 (da)
BR (1) BRPI0813830A2 (da)
CA (1) CA2692612C (da)
CL (1) CL2008002053A1 (da)
DK (1) DK2178900T3 (da)
ES (1) ES2386323T3 (da)
IL (1) IL202940A (da)
PE (1) PE20090823A1 (da)
PL (1) PL2178900T3 (da)
PT (1) PT2178900E (da)
RU (1) RU2476439C2 (da)
TW (1) TWI363060B (da)
WO (1) WO2009010270A2 (da)
ZA (1) ZA201000283B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR067536A1 (es) * 2007-07-17 2009-10-14 Hoffmann La Roche Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
CL2008002053A1 (es) * 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
ES2435272T3 (es) * 2008-09-23 2013-12-17 F. Hoffmann-La Roche Ag Purificación de la eritropoyetina
WO2011035282A1 (en) * 2009-09-21 2011-03-24 Ge Healthcare Bio-Sciences Ab Dual capture separation
PL2616101T3 (pl) * 2010-09-14 2015-01-30 Hoffmann La Roche Sposób oczyszczania pegylowanej erytropoetyny
CN102816227A (zh) * 2012-08-30 2012-12-12 深圳赛保尔生物药业有限公司 回收***的方法
CN105820232B (zh) * 2016-04-08 2019-05-17 昂德生物药业有限公司 单修饰聚乙二醇重组人促红素的制备方法及其制品和应用
CN109415427A (zh) * 2016-07-15 2019-03-01 豪夫迈·罗氏有限公司 用于纯化聚乙二醇化的***的方法
US11518781B2 (en) 2017-12-29 2022-12-06 Hoffmann-La Roche Inc. Process for providing PEGylated protein composition
JP7137625B2 (ja) * 2017-12-29 2022-09-14 エフ．ホフマン－ラ ロシュ アーゲー Ｐｅｇ化タンパク質組成物を提供するための方法
JP7227633B2 (ja) * 2017-12-29 2023-02-22 エフ． ホフマン－ラ ロシュ エージー． Ｐｅｇ化タンパク質組成物を提供するための方法
KR20210090649A (ko) * 2018-11-05 2021-07-20 브리스톨-마이어스 스큅 컴퍼니 Peg화 단백질의 정제 방법
US20240092883A1 (en) * 2019-10-11 2024-03-21 Coherus Biosciences, Inc. Methods of purifying ranibizumab or a ranibizumab variant

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118796A (en) 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
DE69032809T2 (de) 1989-11-06 1999-07-08 Cell Genesys Inc Herstellung von Proteinen mittels homologer Rekombination
EP0779362B2 (en) 1989-12-22 2012-06-13 Laboratoires Serono SA DNA constructs for endogenous gene activation and expression modification
FR2656531B1 (fr) 1989-12-29 1992-04-24 Sanofi Sa Promoteur artificiel pour l'expression de proteines dans le levure.
JP2826362B2 (ja) * 1990-02-13 1998-11-18 三井化学株式会社 オレフィン重合用固体触媒の製造方法、オレフィン重合用固体触媒およびオレフィンの重合方法
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
CH686212A5 (de) 1992-03-07 1996-02-15 Buehler Ag Geb Verfahren und Vorrichtung zur Manipulation und Portionieren von langen Teigwaren.
DE4118912C1 (da) 1991-06-08 1992-07-02 Biotest Pharma Gmbh, 6072 Dreieich, De
EP0536447A1 (en) 1991-10-11 1993-04-14 Koninklijke Emballage Industrie Van Leer B.V. Exposure meter for use with induction heat sealing of containers
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP1170300A1 (en) 1992-07-13 2002-01-09 Bionebraska, Inc. Method for modification of recombinant polypeptides
US5264555A (en) * 1992-07-14 1993-11-23 Enzon, Inc. Process for hemoglobin extraction and purification
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5437989A (en) * 1992-12-30 1995-08-01 Hoffmann-La Roche Inc. Alcohol/aldehyde dehydrogenase from Gluconobacter oxydans DSM 4025 FERM BP-3812
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
IL118201A (en) 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof
DE19535571A1 (de) * 1995-09-14 1997-03-20 Boehringer Mannheim Gmbh Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
EP0885613A1 (de) 1997-06-21 1998-12-23 Roche Diagnostics GmbH Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin
AU7907398A (en) 1997-06-23 1999-01-04 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
US7101838B2 (en) * 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
DE19734293A1 (de) * 1997-08-08 1999-02-11 Boehringer Mannheim Gmbh Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen
BR9917606A (pt) 1998-11-06 2002-12-31 Bio Sidus S A Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento
DK1147134T3 (da) 1999-01-26 2007-02-05 Neurosearch As Hidtil ukendte kaliumkanaler og gener, der koder for disse kaliumkanaler
ATE246202T1 (de) 1999-01-29 2003-08-15 Hoffmann La Roche Gcsf konjugate
DE50001030D1 (de) 1999-05-10 2003-02-13 Ciba Sc Holding Ag Azofarbstoffe, Verfahren zu deren Herstellung und deren Verwendung zum Färben oder Bedrucken von natürlichen oder synthetischen Materialien
DE19930177B4 (de) 1999-06-30 2007-02-08 Nikolai Vladimirovich Bovin Intermolekular assoziierende Verbindungen und deren Verwendung
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
CA2399832C (en) * 2000-02-11 2011-09-20 Stephen D. Gillies Enhancing the circulating half-life of antibody-based fusion proteins
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
EP1525889A1 (en) * 2000-05-15 2005-04-27 F. Hoffmann-La Roche Ag Liquid pharmaceutical composition containing an erythropoietin derivative
MXPA03005406A (es) * 2000-12-20 2003-09-25 Hoffmann La Roche Conjugados de eritropoyetina.
US6930086B2 (en) 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
US6797299B2 (en) 2002-02-05 2004-09-28 Great Wall Enterprise Co., Ltd. Desalting method for nutritional supplements with animal protein
SE526227C2 (sv) 2002-05-15 2005-08-02 North China Pharmaceutical Group Metod för rening av rekombinant humant serumalbumin
WO2004009627A1 (en) * 2002-07-19 2004-01-29 Cangene Corporation Pegylated erythropoietic compounds
WO2004012773A1 (en) * 2002-07-24 2004-02-12 F. Hoffmann-La Roche Ag Polyalkylene glycol acid additives
HUE033623T2 (en) 2002-09-11 2017-12-28 Genentech Inc protein purification
US7610156B2 (en) * 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US20050008649A1 (en) 2003-06-02 2005-01-13 University Of Miami Chimeric molecules and methods of use
AU2005319099B2 (en) * 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
SE0401951D0 (sv) 2004-07-29 2004-07-29 Amersham Biosciences Ab Chromatography method
WO2006126942A1 (en) * 2005-05-24 2006-11-30 Ge Healthcare Bio-Sciences Ab Regeneration of a chromatography matrix
TWI320788B (en) 2005-05-25 2010-02-21 Hoffmann La Roche Method for the purification of antibodies
GB2428018B (en) 2005-07-06 2010-07-28 Acco Uk Ltd Stapling device
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
DK1931704T3 (da) 2005-10-04 2011-03-14 Zymogenetics L L C Frembringelse og rensning af IL-29
WO2008010061A2 (en) 2006-07-17 2008-01-24 Glenmark Pharmaceuticals S.A. 3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
CL2008002053A1 (es) * 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
AR067536A1 (es) * 2007-07-17 2009-10-14 Hoffmann La Roche Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea

Also Published As

Publication number Publication date
ATE556086T1 (de) 2012-05-15
AR067537A1 (es) 2009-10-14
PE20090823A1 (es) 2009-06-27
RU2010105303A (ru) 2011-08-27
JP5307808B2 (ja) 2013-10-02
CN101889023B (zh) 2013-03-20
TW200914463A (en) 2009-04-01
RU2476439C2 (ru) 2013-02-27
JP2010533664A (ja) 2010-10-28
WO2009010270A8 (en) 2010-04-29
EP2178900A2 (en) 2010-04-28
AR112300A2 (es) 2019-10-16
AU2008277887A1 (en) 2009-01-22
PT2178900E (pt) 2012-06-01
US8889837B2 (en) 2014-11-18
US20110118448A1 (en) 2011-05-19
CA2692612C (en) 2015-02-10
IL202940A (en) 2015-07-30
BRPI0813830A2 (pt) 2015-01-06
TWI363060B (en) 2012-05-01
CN101889023A (zh) 2010-11-17
ZA201000283B (en) 2011-06-29
AU2008277887B2 (en) 2012-12-13
ES2386323T3 (es) 2012-08-17
WO2009010270A2 (en) 2009-01-22
JP5814978B2 (ja) 2015-11-17
EP2178900B1 (en) 2012-05-02
US8138317B2 (en) 2012-03-20
CA2692612A1 (en) 2009-01-22
KR101163297B1 (ko) 2012-07-05
KR20100072169A (ko) 2010-06-30
PL2178900T3 (pl) 2012-10-31
CL2008002053A1 (es) 2009-05-22
WO2009010270A3 (en) 2009-04-30
US20090118476A1 (en) 2009-05-07
JP2013189457A (ja) 2013-09-26

Similar Documents

Publication Publication Date Title
DK2178900T3 (da) Oprensning af pegylerede polypeptider
DK2111555T3 (da) Diagnosticering af præeklampsi
DK2011486T3 (da) Farmaceutiske sammensætninger af rifaximin
DE602008000052D1 (de) Wasserreinigungszusammensetzung
DK2084174T3 (da) Fremstilling af ribofuranosylpyrimidinnukleotider
NO347644B1 (no) Polymorfer
DK2126093T3 (da) Forbedring af proteinfremstilling
DK2219469T3 (da) Modificering af enzymatisk disponerede proteiner
DK3118221T3 (da) Proteiner
DK2700786T3 (da) Modifikation af overførselspassage
DK2513135T3 (da) Fremgangsmåde til oprensning af polypeptider
BRPI0812803A2 (pt) Dessalinização
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener
DK2260873T3 (da) Pcylering af proteiner
BRPI0820677A2 (pt) Misturas de compostos pesticidas
DK2114147T3 (da) Reduktion af bivirkninger af tramadol
UY3776Q (es) Reloj pulsera
BRPI0915394A2 (pt) purificação de citoquinas modificadas
DK2081675T3 (da) Syntese af biodiesel
DK2106388T3 (da) Oprensning af spildevand
DK2170373T3 (da) Termostabilisering af proteiner
DK2124946T3 (da) Anvendelse af N-methylpyridiniumderivater til hepatobeskyttelse
BRPI0922716A2 (pt) purificação de polipeptídeo
ES1064635Y (es) Disposicion de conjuntos conmutadores de pulsador
DK2181065T3 (da) Partialoxidation af carbonhydrider